Aim Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumours with varying clinical expression and behaviour. Because of indolent behaviour of NENs, reviewing and evaluation of epidemiological characteristics is a challenge. The aim of this study was to assess prevalence of NENs at tertiary hospitals considering age, gender, location, and grade. Methods Electronic files were used for a retrospective assessment of the patients with NENs of the gastroenteropancreatic tract and bronchopulmonary system in tertiary hospitals in Bosnia and Herzegovina over the past 15 years (2005-2020). Results Among 438 patients, 291(66.4%) were males and 147 (33.6%) females; the median age was 62 years. The lungs were the most frequent site, 304 (69.4%), followed by the pancreas, 22 (5.0%), colon, 14 (3.2%), stomach, 13 (2.9%), appendix, 13 (2.9%), rectum,11 (2.5%), small intestine, eight (1.8%) and gallbladder, one (0.2%). Metastases were most frequently found in the liver, 35 (8%) and lymph nodes, 15 (3.42%). Conclusion The results were largely consistent with those in literature, including age, gender, location, and the degree of differentiation. Most metastases originated from high-grade tumours and greater impairment of the liver.
Bosman F, Carneiro F, Hruban R, Theise N. WHO Classification of tumors of the digestive system. 4ͭ ͪ Ed. World Health Organization; 2010.
2.
Pavel M, ’toole O, Costa D, Capdevila F, Gross J, Kianmanesh D, et al. Vienna Consensus Conference participants. Neuroendocrinology. 2016. p. 172–85.
3.
Saeed A, Buell J, Kandil E. Surgical treatment of liver metastases in patient with neuroendocrine tumors. Ann Trans Med. 2013. p. 6.
4.
Kandil E, Saeed A, Buell J. Surgical approaches for liver metastases in carcinoid tumors. Gland Surg. 2015. p. 442–6.
5.
Hofland J, Kaltsas G, De H. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020. p. 371–403.
6.
Travis W, Brambilla E, Muller-Hermelink H, Harris C. Pathology &Genetics: Tumors of the Lung, Pleura, Thymus and Heart. IARC Press; 2014.
7.
Kleihues P. World Health Organization classification of Tumours. Pathology and Genetics of Endocrine Organs. IARC Press; 2004.
8.
Modlin I, Lye K, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003. p. 934–59.
9.
Hauso O, Gustafsson B, Kidd M, Waldum H, Drozdov I, Chan A, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008. p. 2655–64.
10.
Lawrence B, Gustafsson B, Chan A, Svejda B, Kidd M, Modlin I. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011. p. 1–18.
11.
Ellis L, Shale M, Coleman M. Carcinoid tumors of the gastrointestinal tract: trend in incidence in England since 1971. Am J Gastroenterol. 2010. p. 2563–9.
12.
Leoncini E, Carioli G, Vecchia L, Boccia C, Rindi S, G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. An Oncol. 2016. p. 68–81.
13.
Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of lowgrade and high-grade neuroendocrine neoplasms. Endocrine. 2017. p. 368–79.
14.
Hodgson N, Koniaris L, Livingstone A, Franceschi D. Gastric carcionoids: a temporal increase with proton pump introduction. Surg Endoscop. 2005. p. 1610–2.
15.
Mccarthy M. Proton Pump Inhibitor Use, hypergastrinemia, and gastric carcinoids-what is the relationship? Int J Mol Sci. 2020. p. 662.
16.
Rindi G, Klimstra D, Abedi-Ardekanib, Asa S, Bosman F, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018. p. 1770–86.
17.
Choe J, Kim K, Kim H, Kim D, Kim K, Hong S, et al. What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for pancreatic neuroendocrine neoplasms? Korean J Radiol. 2019. p. 5–17.
18.
Fraenkel M, Kim M, Faggiano A, De Herder W, Valk G. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endoc Relat Cancer. 2014. p. 153–63.
19.
Korse C, Taal B, Van Velthuysen M, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013. p. 1975–83.
20.
Sandvik O, Søreide K, Gudlaugsson E, Kvaløy J, Søreide J. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg. 2016. p. 226–32.
21.
Lombard-Bohas C, Mitry E, ’toole O, Louvet D, Pillon C, Cadiot D, et al. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology. 2009. p. 217–22.
22.
Jiao X, Li Y, Wang H, Liu S, Zhang D, Zhouy. Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China. Chin J Cancer Res. 2015. p. 258–66.
23.
Begumn M, Plöckingeru, Anlaufm, Rin-Kea, Pöpperlg, Lehnert H, et al. Neuroendocrine tumours of the GI tract--data from the German NET Registry. Zentralbl Chir. 2014. p. 276–83.
24.
Galvánja A, Vallina A, Fonseca P, Gómez-Izquierdo L, García-Carbonero R, González M. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2013. p. 61–72.
25.
Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008. p. 3063–72.
26.
Modlin I, Champaneria M, Chan A, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: The rapid pace of no progress. Am J Gastroenterol. 2007. p. 1464–73.
27.
Fraenkel M, Kim M, Faggiano A, Valk G. Epidemiology of gastroenteropancreatic neuroendocrine tumors. Best Pract Res Clin Gastroenterol. 2012. p. 691–703.
28.
Chauhan A, Yu Q, Rayn, Farooquiz, Huang.
29.
B, Tuckert D, Evers M, Arnold S, Anthony L. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018. p. 19245–54.
30.
Travis W. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin. 2014. p. 257–66.
31.
Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2018. p. 7–30.
32.
Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R. The German NET-Registry: An audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009. p. 349–63.
33.
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davi M, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large perspective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest. 2012. p. 817.
34.
Kourie H, Ghorra C, Rassy M, Kesserouani C, Kattan J. Digestive neuroendocrine tumor distribution and characteristics according to the 2010 WHO Classification: a single institution experience in Lebanon. Asian Pac J Cancer Prev. 2016. p. 2679–81.
35.
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez J, Del Prado M, M, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreaticneuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010. p. 1794–803.
36.
Medrano-Guzman R. Clinical and epidemiological features in 495 gastroenteropancreatic neuroendocrine patients in Mexico. J Clin Oncol. 2017. p. 15687.
37.
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016. p. 2679–86.
38.
Jianu C, Fossmark R, Viset T, Qvigstad G, Sordal O, Mårvik R, et al. Gastric carcinoids after long-term use a proton pump inhibitor. Aliment Pharmacol Ther. 2012. p. 644–9.
39.
Moris D, Tsilimigras D, Vagioss, Ntanasis-Stathopoulos I, Karachaliou G, Papalampros A. Alexandrou A, Blazer DG 3 rd , Felekouras E. Neuroendocrine neoplasms of the appendix: a review of the literature. Anticancer Res. 2018. p. 601–11.
40.
Guo L, Wang C, Tang C. Epidemiological features of gastroenteropancreatic tumors in Chengdu city with a population of 14 milion based on date from a single institution. Asian Pac J Clin Oncol. 2016. p. 284–8.
41.
Tanglh, Shiaj, Soslowra, Dhalld, Wongwd, O’reillye, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008. p. 1429–43.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
